Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tyra Biosciences, Inc. (Nasdaq: TYRA) on April 17, 2026, reporting events that occurred on April 16, 2026. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors approved an increase in the number of authorized directors from nine to ten.
- Director Appointment: Habib J. Dable was appointed as a Class II director, with an initial term expiring at the 2026 annual meeting of stockholders.
- Compensation: Mr. Dable was granted options to purchase 44,400 shares of common stock, vesting in equal monthly installments over 36 months. He will also receive standard cash compensation for board service.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the rationale for the appointment, highlighting Mr. Dable's extensive experience in the biopharmaceutical sector, including his former role as CEO of Acceleron Pharma Inc. and his tenure at Bayer AG. The Board has determined that Mr. Dable is an independent director in accordance with Nasdaq listing requirements.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 44,400 stock options granted to Habib J. Dable.
- Confirm the total number of authorized directors is now ten.
- Review Mr. Dable's current board affiliations (Spyglass Pharma, Relay Therapeutics, Day One Biopharmaceuticals, PepGen) for potential conflicts of interest.
- Check the Company's Non-Employee Director Compensation Program for details on cash compensation amounts.